Kuros Biosciences AG
SIX:KURN
Operating Margin
Kuros Biosciences AG
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
|
Kuros Biosciences AG
SIX:KURN
|
966.4m CHF |
0%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.3B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.6B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.1B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.3B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.2B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
-5%
|
Kuros Biosciences AG
Glance View
Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Kuros Biosciences AG's most recent financial statements, the company has Operating Margin of 0.1%.
You don't have any saved screeners yet